The effect of change in fasting glucose on the risk of myocardial infarction, stroke, and all-cause mortality: a nationwide cohort study by Lee, Gyeongsil et al.
Lee et al. Cardiovasc Diabetol  (2018) 17:51 
https://doi.org/10.1186/s12933-018-0694-z
ORIGINAL INVESTIGATION
The effect of change in fasting glucose 
on the risk of myocardial infarction, stroke, 
and all-cause mortality: a nationwide cohort 
study
Gyeongsil Lee1†, Sung Min Kim2†, Seulggie Choi2, Kyuwoong Kim2, Su‑Min Jeong3, Joung Sik Son3, 
Jae‑Moon Yun3 and Sang Min Park2,3*
Abstract 
Background: The effect of change in blood glucose levels on the risk of cardiovascular disease among individuals 
without diabetes is currently unclear. We aimed to examine the association of change in fasting serum glucose with 
incident cardiovascular disease and all‑cause mortality among representative large population.
Methods: We analyzed the data from retrospective cohort of Korean National Health Insurance Service. In total, 
260,487 Korean adults aged over 40 years, without diabetes mellitus and cardiovascular disease at baseline measured 
change in fasting serum glucose according to the criteria of impaired and diabetic fasting glucose status: normal fast‑
ing glucose (NFG, fasting glucose: < 100 mg/dL), impaired fasting glucose (IFG, fasting glucose: 100.0–125.9 mg/dL), 
and diabetic fasting glucose (DFG, fasting glucose: ≥ 126.0 mg/dL). Compared to the persistently unchanged group 
(i.e. NFG to NFG or IFG to IFG), Cox proportional hazards regression analyses were performed in the changed group to 
obtain the hazards ratio (HR) with 95% confidence interval (CI) for the subsequent median 8‑year myocardial infarc‑
tion, stroke, and all‑cause mortality.
Results: Compared to individuals with persistent NFG (i.e., NFG to NFG), individuals who shifted from NFG to DFG 
had an increased risk of stroke (HR [95% CI]: 1.19 [1.02–1.38]) and individuals who shifted from NFG to IFG or DFG had 
increased risks of all‑cause mortality (HR [95% CI]: 1.08 [1.02–1.14] for NFG to IFG and 1.56 [1.39–1.75] for NFG to DFG). 
Compared to individuals with persistent IFG, individuals who shifted from IFG to DFG had an increased risk of MI and 
all‑cause mortality (HR [95% CI]: 1.65 [1.20–2.27] and 1.16 [1.02–1.33], respectively).
Conclusions: Increasing fasting glucose in non‑diabetic population is associated with risks of the MI, stroke, and all‑
cause mortality, which is more rapid, more severe.
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Background
Diabetes is related to both microvascular and macrovas-
cular complications as well as mortality [1, 2]. In par-
ticular, macrovascular complications such as myocardial 
infarction (MI) and stroke account for 80% of all deaths 
in patients with type 2 diabetes mellitus [3]. Therefore, 
preventing macrovascular complications by controlling 
hyperglycemia is imperative in reducing the risk of car-
diovascular disease and mortality [4–6].
Recent evidence suggests that a prediabetic status may 
also elevate the risk of cardiovascular disease and mor-
tality. A prediabetic status referred to people who have 
impaired fasting glucose (IFG, fasting glucose of 100–
125  mg/dL), impaired glucose tolerance (IGT, 2-h post 
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glucose load of 140–199  mg/dL), or both, according to 
American Diabetes Association [5]. Some studies have 
shown that IGT is superior to IFG as a risk factor for car-
diovascular disease [7–10]. However, the Australian Dia-
betes, Obesity, and Lifestyle Study (AusDiab) reported 
IFG as well as IGT to be an independent predictor of car-
diovascular disease and all-cause mortality [11]. Moreo-
ver, meta-analyses also showed that not only IGT but IFG 
is related to risk of cardiovascular disease [12, 13].
Blood glucose levels in most prior studies, however, 
were assessed only one time, possibly resulting in mis-
classification of IFG or IGT. The effect of change in blood 
glucose levels on the risk of cardiovascular disease among 
people without diabetes are currently unclear. We, there-
fore, aimed to examine the association of change in fast-
ing serum glucose with incident cardiovascular disease 
and all-cause mortality within a large population without 
diabetes using the Korean National Health Insurance Ser-
vice-Nation Health Screening Cohort (NHIS-HEALS).
Methods
Study population
The study population was derived from the NHIS-
HEALS database from January 1, 2002 to December 31, 
2013, which is provided by the NHIS (NHIS-2017-2-
460). In 2000, NHIS was launched by integrating diverse 
medical insurance organizations in Korea. The NHIS has 
provided mandatory health insurance for all Koreans 
since 1989; thus, the enrollment rate is nearly 98% [14]. 
Attrition over follow-up in this database is known to be 
rare because the NHIS acts as a universal health insur-
ance [15]. Enrollees over 40 years of age are required to 
take bi-annual health screening visits, including gather-
ing of clinical and sociodemographic data. Among the 
entire data set from the national health examination, 
10% (about 500,000 participants) of the data are collected 
by simple random sampling with deidentification [15]. 
NHIS-HEALS contains retrospective data, including 
electronic medical records, information on clinical visits, 
diagnosis based on International Classification of Disease 
(ICD) codes, anthropometry, and laboratory examina-
tion. Sociodemographic data on age, sex, income status, 
residential information, and disability status are also 
included. The NHIS plays a role in paying premiums to 
medical institutions. For these reasons, data are known 
to be accurate [15].
A total of 334,377 participants who took at least two 
visits of health screening between the first (from 2002 to 
2003) and second (from 2004 to 2005) health examina-
tions, with fasting serum glucose values, were selected. 
Among these individuals, we excluded 42,097 partici-
pants who were diagnosed with type 2 diabetes before the 
onset of follow-up (index date: January 1, 2006) according 
to the ICD-10 codes (10th revision) by the World Health 
Organization for type 2 diabetes (E11, E12, E14) or those 
with baseline fasting glucose levels ≥ 126.0  mg/dL at 
their first health examination. We further excluded 780 
participants who passed away and 30,753 participants 
who were diagnosed MI or stroke before the index date. 
Then, we removed 122 participants with fasting glucose 
< 50.0  mg/dL and 138 participants without sex values. 
Finally, the study population consisted of 260,487 partici-
pants (149,913 men, 110,574 women).
Data collection
The participants underwent blood examination includ-
ing fasting glucose levels during each health visit. We 
measured changes in fasting serum glucose levels from 
the first health examination to the second health exami-
nation in this study (Fig. 1). Fasting glucose levels of the 
first health examination were divided into two groups: 
normal fasting glucose (NFG, fasting glucose: < 100 mg/
dL) and impaired fasting glucose (IFG, fasting glucose: 
100.0–125.9 mg/dL). Fasting glucose levels of the second 
health examination were divided into 3 groups: NFG, 
IFG, and diabetic fasting glucose (DFG, fasting glucose: 
≥ 126.0  mg/dL). The changes in fasting glucose were 
defined as the shift from each fasting glucose level of the 
first health examination (baseline) to each fasting glucose 
of the second health examination after 2 years.
The main outcomes of this study were hospitalizations 
due to MI or stroke, and all-cause mortality that occurred 
from January 1, 2006 and December 31, 2013. ICD-10 
codes were used to identify and classify the outcomes: 
MI (I21–I24), stroke (I60–69). Hospitalization due to car-
diovascular events was defined as participants who were 
hospitalized for 2 days or more due to the relevant dis-
ease, in order to exclude admissions for other diseases.
Covariates were based on the data from near before 
index year included age, sex, socioeconomic status (low 
and high), body mass index (BMI, kg/m2), smoking sta-
tus (never and ever), alcohol consumption (none, < 3, 
and ≥ 3 times per week), physical activity (no, < 3, and 
≥ 3 times per week), systolic/diastolic blood pressure 
(mmHg), total cholesterol (mg/dL), Charlson Comorbid-
ity Index (CCI, 0, 1–2, and ≥ 3). Participants were clas-
sified as underweight, normal weight, overweight, and 
obese based on the Asian criteria [16]. CCI is the most 
commonly used comorbidity index for predicting mortal-
ity [17, 18].
Statistical analysis
Cox proportional hazards regression analyses were 
performed to obtain the hazards ratio (HR) with 95% 
confidence interval (CI) of MI, stroke, and all-cause 
mortality for each NFG and IFG group at the first health 
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examination, after adjusting for age, sex, socioeconomic 
status, BMI, smoking status, alcohol consumption, physi-
cal activity, CCI, blood pressure, total cholesterol, and 
baseline fasting glucose level. Among covariates, age, 
BMI, blood pressure, total cholesterol and fasting glucose 
were dealt with continuous variables. Those with persis-
tently unchanged fasting glucose (NFG at the first health 
examination to NFG at the second health examination 
and IFG at the first health examination to IFG at the sec-
ond health examination) were considered the reference 
group. Stratified analyses were conducted including age, 
sex, and BMI in order to identify potential subgroups that 
show a significant association between change in fast-
ing glucose and MI, stroke, and all-cause mortality. After 
excluding participants who were diagnosed with myo-
cardial infarction or stroke, or who died between Janu-
ary 1, 2006 and December 31, 2006, and between January 
1, 2006 and December 31, 2007, sensitivity analyses were 
performed to enhance the reliability of the association 
between change in fasting glucose levels and MI, stroke, 
and mortality. All data mining and statistical analyses in 
this study were conducted using SAS 9.4 (SAS Institute, 
Cary, NC, USA) and STATA 13.0 (StataCorp LP, College 
Station, TX, USA). Statistical significance of this study 
was defined as a two-sided p value less than 0.05.
Results
260,487 individuals without diabetes were followed up 
to an average of 8  years (standard deviation, SD 0.9), 
resulting in 2,042,960 person-years. During the follow-
up, the number of incident MI, incident stroke, and 
all-cause mortalities were 1318 (0.5%), 8144 (3.13%), 
10,065 (3.86%), respectively. The baseline characteristics 
of study participants are presented in Table 1. Those who 
belonged to the NFG group at the baseline were more 
likely to be younger women, with a lower BMI, never 
smokers, with a lower alcohol consumption, lower blood 
pressure, and lower total cholesterol than those who were 
in the IFG group at baseline.
Figure 2 shows adjusted cumulative hazard curves for 
8-year MI, stroke, and all-cause mortality by changes in 
fasting glucose, after adjusting for age, socioeconomic 
status, smoking habit, alcohol consumption, physical 
activity, BMI, CCI, blood pressure, and fasting glucose at 
baseline. Compared to individuals with persistent NFG 
(i.e., NFG to NFG), individuals who shifted from NFG to 
DFG had an increased risk of stroke (HR [95% CI]: 1.19 
[1.02–1.38]) and individuals who shifted from NFG to 
IFG or DFG had increased risks of all-cause mortality 
(HR [95% CI]: 1.08 [1.02–1.14] for NFG to IFG and 1.56 
[1.39–1.75] for NFG to DFG). Compared to individuals 
with persistent IFG, individuals who shifted from IFG to 
DFG had an increased risk of MI and all-cause mortal-
ity (HR [95% CI]: 1.65 [1.20–2.27] and 1.16 [1.02–1.33], 
respectively).
Subgroup analyses using the multivariable model 
of MI, stroke, and all-cause mortality risks by changes 
in fasting glucose from NFG and IFG are shown in 
Tables  2, 3, 4. Individuals who were 65  years or older 
had an increased risk for MI. With regard to all-cause 
mortality, results of all subgroups stratified by age, 











NFG, IFG, or DFG





Median 8-year follow-up 
of MI, stroke, and all-cause mortality according to 
change in fasting glucose status
Fig. 1 Timeline of the study design. Subjects without diabetes and cardiovascular disease performed 2‑year fasting serum glucose examination. 
The first fasting glucose status was categorized into two groups, normal fasting glucose [(NFG), fasting serum glucose: < 100.0 mg/dL] and impaired 
fasting glucose [(IFG), fasting serum glucose: 100.0–125.9 mg/dL] (individuals with more than 126 mg/dL were excluded). The second fasting 
glucose status was categorized into three groups, NFG, IFG, and diabetic fasting glucose [(DFG), fasting serum glucose: ≥ 126.0 mg/dL]. Accordingly, 
six categories based on the change in fasting glucose level were followed up during 8 years for determining the risk of myocardial infarction (MI), 
stroke, and all‑cause mortality
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magnitude of HRs of all-cause mortality was higher in 
patients who were more than 50 years old than in those 
less than 50  years, in men than in women, and those 
with BMI ≥ 25  kg/m2 (obese based on Asian criteria) 
than with BMI < 25 kg/m2.
The results of the sensitivity analyses based on the mul-
tivariable model of MI, stroke, and all-cause mortality 
risks, in relation to changes in fasting glucose, from NFG 
and IFG, are shown in  Additional file  1: Tables S1 and 
S2. The results were almost similar to the results shown 
in Fig. 2.
Discussion
In this general population-based, retrospective cohort 
study with more than 2,000,000 person-years of follow-
up, we examined the association between 2-year change 
in fasting serum glucose and risk of cardiovascular dis-
ease and all-cause mortality after a median follow-up 
of 8  years, after adjusting for cardiovascular covariates. 
Among individuals with NFG at the first health exami-
nation, individuals who shifted to IFG were more, and 
a shift to DFG after 2  years was associated with much 
higher risks of stroke and all-cause mortality, compared 
Table 1 Baseline characteristics of study participants
SD standard deviation, NGT normal glucose tolerance, IFG Impaired fasting glucose, BMI body mass index, CCI Charlson comorbidity index, BP blood pressure
Participants were classified as underweight, normal weight, overweight, and obese based on the Asian criteria
Fasting glucose (mg/dL)
NFG (< 100.0 mg/dL) IFG (100.0–125.9 mg/dL) p value
Number of subjects, n 198,560 61,927
Age, years, mean (SD) 53.5 (8.6) 54.7 (8.9)
 40–49, % 41.6 35.8 < 0.001
 50–59, % 34.8 35.9
 60–69, % 17.5 20.9
 ≥ 70, % 6.1 7.4
Sex, %
 Men 55.3 64.6
 Women 44.7 35.4
Socioeconomic status, %
 Low 34.2 35.4 < 0.001
 High 65.5 64.2
BMI, kg/m2, mean (SD) 23.7 (2.8) 24.2 (2.9)
 <18.5, % 2.5 1.9 < 0.001
 18.5‑22.9, % 39.2 32.8
 23‑24.9, % 27.8 28.3
 ≥25, % 30.5 37.0
Smoking status, %
 Never smoker 66.2 61.4 < 0.001
 Ever smoker 29.8 34.6
Alcohol consumption, per week, %
 < 3 times 88.9 84.9 < 0.001
 ≥ 3 times 9.5 13.6
Physical activity, per week, %
 < 3 times 76.2 75.9 0.092
 ≥ 3 times 21.6 22.0
CCI, %
 0 36.5 36.8 < 0.001
 1–2 50.9 49.5
 ≥ 3 12.6 13.7
Systolic BP, mmHg, mean (SD) 124.6 (16.7) 128.1 (17.1) < 0.001
Diastolic BP, mmHg, mean (SD) 78.3 (11.0) 80.3 (11.1) < 0.001
Total cholesterol, mg/dL, mean (SD) 197.3 (36.0) 200.1 (37.1) <0.001
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to persistent NFG. Among individuals with IFG at the 
first health examination, compared to persistent IFG, 
individuals who shifted to DFG had higher risks of MI 
and all-cause mortality.
One study examined the effects of change in fasting 
glucose over time, which was in line with our results. 
Fasting glucose variabilities are associated with subse-
quent risks of MI in non-diabetic patients [19]. Other 
previous studies were also consistent with our findings, 
although they did not report a change in fasting glu-
cose but rather one-time fasting glucose level. AusDiab 
study reported that all-cause mortality was greater for 
IFG than for NFG among 10,428 participants after a 
median follow-up period of 5.2  years [11]. Additionally, 
two meta-analyses showed that elevated fasting glucose 
was associated with the risk of cardiovascular disease in 
people without diabetes [12, 13]. A prospective study of 
a large cohort in Korea reported that IFG is associated 
with the risk of stroke and coronary heart disease [20]. 
Another prospective national survey in Israel reported 
that a linear association between admission blood glu-
cose and 10-year mortality among heart failure patients 
without diabetes [21].
By contrast, some have reported that IFG is less likely 
to be a risk factor for cardiovascular disease compared 
to IGT [7–10]. The differences between the findings of 
these prior studies and the present study could originate 
from differences in sample size or from the use of differ-
ent methods of fasting glucose analysis. Data from sev-
eral different centers in different countries demonstrate 
that there is no uniform method for examining fast-
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Fig. 2 Adjusted cumulative hazard curves for 8‑year MI, stroke, and all‑cause mortality by change in fasting glucose. Hazard ration analyzed by 
Cox proportional hazards regression analysis adjusted for age, sex, socioeconomic status, physical activity, smoking status, alcohol consumption, 
body mass index, blood pressure, total cholesterol, Charlson comorbidity index, and baseline fasting glucose level. MI myocardial infarction, NFG 
normal fasting glucose, IFG impaired fasting glucose, DFG diabetic fasting glucose. a Cumulative hazard of MI among individuals with NFG at the 1st 
examination. b Cumulative hazard of stroke among individuals with NFG at the 1st examination. c Cumulative hazard of all‑cause mortality among 
individuals with NFG at the 1st examination. d Cumulative hazard of MI among individuals with IFG at the 1st examination. e Cumulative hazard of 
stroke among individuals with IFG at the 1st examination. f Cumulative hazard of all‑cause mortality among individuals with IFG at the 1st examina‑
tion
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misclassification of fasting glucose status. However, most 
single large cohorts such as that mentioned above used 
a uniform analysis method for evaluating fasting glucose, 
which led to the indication that an IFG could be a sig-
nificant predictor for cardiovascular disease risks like our 
findings.
Compared to persistent IFG, shift to DFG from IFG 
during 2 years (i.e. more rapid change in fasting glucose 
compare to shift to persistent IFG) was associated with 
a higher risk of cardiovascular and all-cause mortality, 
which could imply that glycemic control could slow or 
halt the progression of macrovascular complications and 
all-cause mortality, in line with previous studies [21–24]. 
In Korea, when participants revealed an IFG status in the 
national health screening program, they received an advi-
sory opinion via a letter from a doctor, including sugges-
tions for lifestyle modifications and a recommendation 
for follow-up 3–6 months later in nearby clinics. Accord-
ing to this advisory opinion, people with prediabetes 
status intentionally aim to elicit a reduction in hyper-
glycemia through lifestyle modification such as healthy 
diets, exercise, quitting smoking, or abstemious in drink-
ing. Accordingly, early detection of IFG via screening of 
glycemic status could be one of the strategy to prevent 
mortality. However, the shift to NFG from IFG is not sig-
nificantly associated with the risk of cardiovascular dis-
ease, which may be due to minor events.
The Cardiovascular Heart Study in the U.S. reported 
no evidence that prediabetes is associated with subse-
quent 13-year incident cardiovascular events or mortality 
in community-dwelling adults aged more than 65  years 
[25]. In our subgroup analysis of participants older than 
65 years, the shift to IFG or DFG from NFG was not also 
significantly associated with risk of MI or stroke; how-
ever, it was associated with all-cause mortality. Other 
previous studies were consistent with our results. Among 
hospitalized patients with heart failure without pre-
existing diabetes, there was a linear relationship between 
Table 2 Subgroup analysis of the associations between change in fasting glucose and the risk of myocardial infarction
Hazard ratio analyzed by Cox proportional hazards regression analysis adjusted for age, sex, socioeconomic status, physical activity, smoking status, alcohol 
consumption, body mass index, blood pressure, total cholesterol, Charlson comorbidity index, and baseline fasting glucose level
n number, HR hazard ratio, CI confidential interval, NFG normal fasting glucose (< 100.0 mg/dL), IFG impaired fasting glucose (100.0–125.9 mg/dL), DFG diabetic fasting 
glucose (≥ 126.0 mg/dL)
Fasting glucose level 
at baseline (mg/dL)
NFG (< 100.0 mg/dL) IFG (100.0–125.9 mg/dL)














Age < 65 years
 Subtotal (N) 136,764 32,057 3188 28,272 19,977 3615
 Number of cases (n) 482 151 15 124 92 31
 HR (95% CI) 1 1.06 (0.88–1.28) 0.85 (0.51–1.42) 1.15 (0.88–1.51) 1 1.49 (0.98–2.25)
Age ≥ 65 years
 Subtotal (N) 19,957 5765 829 5335 3879 849
 Number of cases (n) 199 74 12 65 51 22
 HR (95% CI) 1 1.23 (0.94–1.61) 1.26 (0.69–2.32) 0.93 (0.64–1.34) 1 2.02 (1.21–3.35)
Men
 Subtotal (N) 83,348 23,763 2790 20,418 16,354 3240
 Number of cases (n) 539 183 20 147 120 43
 HR (95% CI) 1 1.10 (0.93–1.31) 0.92 (0.58–1.43) 1.04 (0.81–1.32) 1 1.57 (1.10–2.23)
Women
 Subtotal (N) 73,373 14,059 1227 13,189 7502 1224
 Number of cases (n) 142 42 7 42 23 10
 HR (95% CI) 1 1.11 (0.78–1.57) 1.25 (0.55–2.85) 1.16 (0.69–1.95) 1 2.11 (0.99–4.47)
BMI < 25.0 kg/m2
 Subtotal (N) 111,438 24,195 2411 22,436 14,195 2368
 Number of cases (n) 439 138 15 112 81 27
 HR (95% CI) 1 1.14 (0.94–1.38) 0.91 (0.54–1.56) 0.98 (0.74–1.31) 1 1.71 (1.10–2.65)
BMI ≥ 25.0 kg/m2
 Subtotal (N) 45,255 13,615 1605 11,157 9651 2095
 Number of cases (n) 242 87 12 77 62 26
 HR (95% CI) 1 1.05 (0.82–1.35) 1.10 (0.62–1.98) 1.19 (0.85–1.67) 1 1.63 (1.02–2.60)
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admission glucose level and 10-year mortality [21]. 
Although heart failure could be the direct cause of death, 
higher fasting glucose may be an additional contributor 
to mortality. The difference between the present study 
and Cardiovascular Heart Study in U.S. is the presence of 
an independent variable (i.e. change in fasting glucose vs. 
one-time measurement of fasting glucose). Accordingly, 
although a prediabetic status itself was not significant 
among the elderly, increasing fasting glucose was associ-
ated with all-cause mortality.
There are some possible mechanisms reported. Abnor-
mal glucose status disrupts normal endothelial function 
by oxidative stress [26], protein kinase C activation, and 
advanced glycated end product receptor activation [27], 
thereby accelerates atherosclerotic plaque formation as 
well as increasing arterial stiffness [28]. IFG status has also 
been associated with arterial endothelial dysfunction and 
intima-media thickening [29], which linked to incident 
MI and stroke [30, 31]. Furthermore, a series of experi-
mental studies demonstrated that variability in blood glu-
cose may be more prejudiced to increase cardiovascular 
disease than constantly high blood glucose [31–34].
There are limitations to our study that need to be 
noted. First, the development of MI and stroke confirmed 
Table 3 Subgroup analysis of the associations between change in fasting glucose and the risk of stroke
Hazard ratio analyzed by Cox proportional hazards regression analysis adjusted for age, sex, socioeconomic status, physical activity, smoking status, alcohol 
consumption, body mass index, blood pressure, total cholesterol, Charlson comorbidity index, and baseline fasting glucose level





















Age < 65 years
 Subtotal (N) 136,764 32,057 3188 28,272 19,977 3615
 Number of cases 
(n)
2687 747 95 703 518 107
 HR (95% CI) 1 1.06 (0.97–1.15) 1.19 (0.97–1.47) 1.03 (0.91–1.15) 1 1.01 (0.82–1.24)
Age ≥ 65 years
 Subtotal (N) 19,957 5765 829 5335 3879 849
 Number of cases 
(n)
1726 527 87 479 366 102
 HR (95% CI) 1 1.04 (0.95–1.15) 1.20 (0.97–1.50) 0.99 (0.87–1.14) 1 1.22 (0.98–1.53)
Men
 Subtotal (N) 83,348 23,763 2790 20,418 16,354 3240
 Number of cases 
(n)
2416 790 117 717 599 149
 HR (95% CI) 1 1.05 (0.97–1.14) 1.16 (0.96–1.40) 1.00 (0.90–1.12) 1 1.08 (0.90–1.30)
Women
 Subtotal (N) 73,373 14,059 1227 13,189 7502 1224
 Number of cases 
(n)
1997 484 65 465 285 60
 HR (95% CI) 1 1.03 (0.94–1.14) 1.25 (0.97–1.60) 1.03 (0.89–1.20) 1 1.08 (0.82–1.43)
BMI < 25.0 kg/m2
 Subtotal (N) 111,438 24,195 2411 22,436 14,195 2368
 Number of cases 
(n)
3030 819 113 756 534 114
 HR (95% CI) 1 1.06 (0.98–1.15) 1.18 (0.97–1.42) 0.97 (0.87–1.09) 1 1.07 (0.88–1.32)
BMI ≥ 25.0 kg/m2
 Subtotal (N) 45,255 13,615 1605 11,157 9651 2095
 Number of cases 
(n)
1383 455 69 426 349 95
 HR (95% CI) 1 1.00 (0.90–1.12) 1.20 (0.94–1.53) 1.09 (0.94–1.26) 1 1.12 (0.89–1.41)
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by hospitalization for 2  days or more for the relevant 
disease based on ICD-10 codes, which are conceivable 
to underestimate the actual number of cardiovascular 
disease cases. However, a previous study showed that 
identifying cardiovascular disease events via the ICD-
10 code has an accuracy higher than 80% [35]. Second, 
future development of diabetes during follow-up period 
is hard to consider, despite the fact that the risk of major 
adverse cardiovascular events is significantly greater in 
diabetic patients who have a longer illness duration [36]. 
However, we investigated the 2-year change in fasting 
glucose, which could distinguish the progression to DFG 
from NFG or IFG status. Third, participants in this study 
were older than the middle-aged, and the elderly may 
already have subclinical cardiovascular disease. However, 
among patients with heart failure, high glucose level was 
associated with mortality [21]. In addition, some studies 
reported that target organ damage precedes the clini-
cal appearance of diabetes [37]. Lastly, fasting glucose 
was assessed through serum, not plasma as was recom-
mended [5], which induced an error in the serum analy-
ses of 1.15% compared to plasma analyses [38]. This error 
may generate when the sample is stored at room temper-
ature after drawing blood; however, the error is very low 
Table 4 Subgroup analysis of the associations between change in fasting glucose and the risk of all-cause morality
Hazard ratio analyzed by Cox proportional hazards regression analysis adjusted for age, sex, socioeconomic status, physical activity, smoking status, alcohol 
consumption, body mass index, blood pressure, total cholesterol, Charlson comorbidity index, and baseline fasting glucose level
n number, HR hazard ratio, CI confidential interval, NFG normal fasting glucose (< 100.0 mg/dL), IFG impaired fasting glucose (100.0–125.9 mg/dL), DFG, diabetic 




















Age < 65 years
 Subtotal (N) 136,764 32,057 3188 28,272 19,977 3615
 Number of cases 
(n)
2,5864 746 146 700 541 137
 HR (95% CI) 1 1.07 (0.98–1.16) 1.72 (1.46–2.04) 0.94 (0.84–1.05) 1 1.23 (1.02–1.48)
Age ≥ 65 years
 Subtotal (N) 19,957 5765 829 5335 3879 849
 Number of cases 
(n)
2661 855 168 816 579 152
 HR (95% CI) 1 1.11 (1.03–1.20) 1.46 (1.25–1.71) 1.01 (0.91–1.13) 1 1.17 (0.98–1.40)
Men
 Subtotal (N) 83,348 23,763 2790 20,418 16,354 3240
 Number of cases 
(n)
3726 1213 252 1123 842 214
 HR (95% CI) 1 1.07 (1.01–1.14) 1.60 (1.40–1.82) 1.01 (0.92–1.11) 1 1.12 (0.96–1.30)
Women
 Subtotal (N) 73,373 14,059 1227 13,189 7502 1224
 Number of cases 
(n)
1499 388 62 393 278 75
 HR (95% CI) 1 1.09 (0.97–1.22) 1.36 (1.06–1.76) 0.87 (0.75–1.02) 1 1.29 (0.99–1.67)
BMI < 25.0 kg/m2
 Subtotal (N) 111,438 24,195 2411 22,436 14,195 2368
 Number of cases 
(n)
3983 1188 224 1160 777 193
 HR (95% CI) 1 1.11 (1.04–1.18) 1.50 (1.31–1.72) 1.00 (0.92–1.10) 1 1.21 (1.03–1.42)
BMI ≥ 25.0 kg/m2
 Subtotal (N) 45,255 13,615 1605 11,157 9651 2095
 Number of cases 
(n)
1241 412 90 355 343 96
 HR (95% CI) 1 1.00 (0.89–1.12) 1.65 (1.33–2.04) 0.92 (0.79–1.07) 1 1.08 (0.86–1.36)
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because the NHIS recommends refrigeration of the sam-
ple at health screening centers. Despite these limitations, 
these findings show representative results based on data 
from a nationwide NHIS database [15].
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